Status:
RECRUITING
Therapeutic Drug Monitoring of Beta-lactams and Renal Hyperclearance in Patients Admitted to Intensive Care for Acute Brain Injury
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Critical Illness
Brain Injuries
Eligibility:
All Genders
18+ years
Brief Summary
Augmented Renal Clearance (ARC), defined as a supraphysiological increase in renal function, is frequently observed in critically ill patients, particularly those with acute brain injury. ARC complica...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years old)
- Admitted to the intensive care unit for acute brain injury
- Exhibiting Augmented Renal Clearance (ARC), defined by a urinary creatinine clearance (ClCrU) greater than 130 mL/min/1.73 m² on at least one measurement
- Receiving Therapeutic Drug Monitoring (TDM)-guided treatment with one of the following beta-lactam antibiotics: amoxicillin/clavulanic acid, cefotaxime, piperacillin/tazobactam, cefepime, or meropenem
- Affiliated with or benefiting from a health insurance scheme
Exclusion
- Estimated life expectancy \<24 hours
- Patients who have expressed opposition to study participation
- Patients under legal protection (guardianship, curatorship, or court protection)
- Patients currently in an exclusion period determined by participation in another study
- Patients already enrolled in a study that precludes concurrent participation in an observational study
Key Trial Info
Start Date :
May 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06999161
Start Date
May 5 2025
End Date
December 1 2025
Last Update
May 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France, 30029